HIGHLANDS RANCH, CO., July 17, 2009-
Zipline Performance Group, a leader in consulting and training services for organizations and businesses in healthcare and other industries, today announced an agreement with the Colorado Prevention Center (CPC). Zipline will provide sales and marketing services to bring CPC's highly respected training programs to a wide audience. CPC's training is designed for clinical research coordinators, principal investigators and others in the area of clinical trials.
Leading the Zipline team will be Tom Brooksher, President and CEO, and Erik Hultman, Vice President of Sales. Both Brooksher and Hultman are veterans in designing highly effective sales, marketing and performance strategies. Mr. Brooksher has 30-plus years of successful experience in helping businesses and organizations, especially in healthcare, market and sell their training and information services. Mr. Hultman also brings an extensive background in sales and marketing for training and workforce performance services in healthcare, communications and other markets.
Based in Denver,
CPC
is a world-renowned non-profit academic research organization and community disease prevention center. Its mission is to improve health by conducting clinical research and integrating scientific findings into the practice of preventive medicine. CPC serves as a clinical trials research base and a prevention outreach facility in conjunction with the University of Colorado Denver, the Denver Health and Hospital Authority, and the National Jewish Medical and Research Center. CPC also reaches out to the community to provide preventive healthcare services and education programs, particularly in the area of cardiovascular disease, hypertension and diabetes.
With expertise in every aspect of clinical research, CPC is uniquely positioned to provide training for the conduct of clinical trials. CPC's current course, "Clinical Trials Training for Clinical Research Coordinators and Principal Investigators," has proven successful in training CPC's own workforce and partners over the past few years. The core course is available as an eight-hour, instructor-led course as well as a blended classroom-and-online program, using the innovative Confidence-Based LearningTM platform. CPC also offers an advanced level of the course available in an eight-hour, instructor-led program that covers clinical trials in depth. CPC also plans to announce more courses in the near future.
"CPC possesses academic, medical and scientific expertise in the areas of clinical research and prevention outreach services that are recognized not only in Colorado but around the world," Mr. Brooksher said. "As CPC begins to bring its training programs to a broad audience, it will lead the pack. Zipline is proud to assist CPC in this effort by offering our specialized sales and marketing services."
About Zipline Performance Group
Zipline offers an extensive platform of consulting services, custom program development and a catalog of customized learning solutions. Zipline is also a pioneer in Confidence-Based LearningTM (CBL) and one of the leading CBL developers in the world. Zipline's programs and services enable employees to accomplish more in less time; make fewer costly mistakes; increase customer satisfaction and retention; and increase revenue by growing sales, launching new products or expanding into new markets. Founded by Tom Brooksher, an expert in corporate education, distance learning and online programs, Zipline is based in Highlands Ranch, Colo. For more information, visit
www.ziplineperformance.com
.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.